Skip to main content

Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12

  • 2021-01
  • OncoImmunology 10(1)
    • Qingxiang Li
    • Yuke Li
    • Yifei Wang
    • Le Xu
    • Yuxing Guo
    • Yixiang Wang
    • Lin Wang
    • Chuanbin Guo

Abstract

Recent advances in immunotherapy, as a part of the multidisciplinary therapy, has gradually gained more attention. However, only a small proportion of patients who sensitive to the therapy could gain benefits. An increasing number of studies indicate that intestinal microbiota could enhance the efficiency of cancer immunotherapy. As one of the main probiotics, Bifidobacterium plays an important role in immune regulation, which has been proved by animal research and human clinical study. But the detailed mechanism was not clearly elucidated. Here we found oral administration of Bifidobacterium breve (B. breve) lw01 could significantly inhibit tumor growth and up-regulate tumor cell apoptosis, which relied on the recruitment of tumor-infiltrating lymphocytes and dendritic cells (DCs) in tumor microenvironment, but not Lactobacillus rhamnosus (L. rhamnosus) CGMCC 1.3724 or Escherichia coli (E. coli) MG1655. In the in situ ligated intestine loop model, B. breve's stimulation triggered the upregulated expression of DC-related chemokine CCL20 and recruited more DCs in the intestinal villi. Further study revealed the enhancement of interleukin 12 (IL-12) secretion derived from DCs is essential to B. breve's antitumor effect, which was counteracted by the treatment of neutralizing antibody for IL-12. Meanwhile, the modulation of intestinal microbiota caused by exogenous B. breve might enhance its antitumor effect. This study provides a simple and easy way to promote antitumor immunity via B. breve.

Keywords: Bifidobacterium breve; dendritic cells; interleukin 12; intestinal microbiota; solid tumor.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium breveIncreased Tumor Cell DeathBeneficial
Large
Bifidobacterium breveReduced Tumor GrowthBeneficial
Large
Bifidobacterium breve R0070Enhanced Dendritic Cell Recruitment in Intestinal VilliBeneficial
Moderate
Bifidobacterium breve R0070Improved Gut MicrobiotaBeneficial
Moderate
Bifidobacterium breve R0070Increased Cancer Cell ApoptosisBeneficial
Large
Bifidobacterium breve R0070Increased Interleukin 12 Secretion from Dendritic CellsBeneficial
Moderate
Bifidobacterium breve R0070Reduced Tumor GrowthBeneficial
Large
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.